Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kura Oncology (KURA) EBITDA Margin (2024 - 2025)

Historic EBITDA Margin for Kura Oncology (KURA) over the last 2 years, with Q3 2025 value amounting to 385.53%.

  • Kura Oncology's EBITDA Margin fell 132071300.0% to 385.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 476.31%, marking a year-over-year change of. This contributed to the annual value of 319.11% for FY2024, which is 97361600.0% down from last year.
  • Latest data reveals that Kura Oncology reported EBITDA Margin of 385.53% as of Q3 2025, which was down 132071300.0% from 475.31% recorded in Q2 2025.
  • Over the past 5 years, Kura Oncology's EBITDA Margin peaked at 12821.6% during Q3 2024, and registered a low of 475.31% during Q2 2025.